Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis

Published:2020-01-06 Issue:1 Volume:7 Page:165-171
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Best Jennie H.,Vlad Steven C.,Pei Jinglan

Funder

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s40744-019-00191-6.pdf

Reference25 articles.

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(1):1–12.

2. Kobelt G, Woronoff A-S, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008;75(4):408–15.

3. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48(10):2750–62.

4. ACTEMRA Prescribing Information. Genentech, Inc. South San Francisco, CA. 2019.

5. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis;Journal of Personalized Medicine;2022-02-25

2. MiR-140-3p inhibits the cell viability and promotes apoptosis of synovial fibroblasts in rheumatoid arthritis through targeting sirtuin 3;Journal of Orthopaedic Surgery and Research;2021-02-02

3. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry;Rheumatology International;2021-01-02

4. Biomarkers and pharmacoeconomics in rheumatoid arthritis: a good marriage;Journal of Medical Economics;2020-05-21